Iberin for Health & Longevity

Evidence Review created on 04/27/2026 using AI4L / Opus 4.7

Also known as: 3-(Methylsulfinyl)propyl Isothiocyanate, IBN, IBR, 1-Isothiocyanato-3-(methylsulfinyl)propane

Motivation

Iberin is a sulfur-containing plant compound formed when cells in cabbage, broccoli, kale, horseradish, and other cruciferous vegetables are crushed or chewed. It is a close relative of sulforaphane and, like sulforaphane, switches on the body’s internal antioxidant and detoxification defenses.

Iberin sits in the shadow of its better-studied homologue. While sulforaphane has dominated cruciferous-vegetable research for three decades, iberin has accumulated only a small but growing body of laboratory and animal studies on cancer cell biology, inflammation, antimicrobial activity, and antioxidant signaling. No human clinical trials have tested iberin as a standalone intervention; whatever exposure people obtain comes through eating cruciferous vegetables alongside other related compounds.

This review examines what is known about iberin as a longevity-relevant compound — what it is, how it forms and is metabolized, the preclinical evidence for its proposed benefits, the practical risks, and the realistic ways to increase iberin exposure given the absence of standalone supplements and human outcome data.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No dedicated Grokipedia article for iberin (the isothiocyanate) exists as of 04/27/2026.

Examine

No dedicated Examine.com page for iberin exists as of 04/27/2026.

ConsumerLab

No dedicated ConsumerLab.com review or product-testing page for iberin exists as of 04/27/2026.

Systematic Reviews

No systematic reviews or meta-analyses for iberin were found on PubMed as of 04/27/2026.

Mechanism of Action

Iberin (3-methylsulfinylpropyl isothiocyanate) is the hydrolysis product of the glucosinolate glucoiberin, which is found in cabbage, broccoli, Brussels sprouts, horseradish, kale, and several less common Brassicaceae. When plant cells are damaged by chewing, chopping, or chewing-equivalent mechanical disruption, the plant enzyme myrosinase (a thioglucosidase that cleaves glucosinolates into reactive aglycones) converts glucoiberin into iberin. In the gut, certain myrosinase-active bacteria (e.g., Enterococcus casseliflavus, Escherichia coli VL8) can also generate iberin from glucoiberin, although gut conversion is variable and often inefficient compared to pre-formed iberin from raw or minimally processed crucifers.

Iberin’s biological effects are mediated by several interconnected pathways:

Nrf2/Keap1 activation: Iberin reacts with cysteine residues on Keap1 (Kelch-like ECH-associated protein 1, a sensor protein that normally tags the transcription factor Nrf2 for destruction). Modification of Keap1 releases Nrf2, which translocates into the nucleus and switches on phase II detoxification and antioxidant genes including HO-1 (heme oxygenase 1, an enzyme that breaks down heme and produces antioxidants), NQO1 (NAD(P)H quinone oxidoreductase 1, an enzyme that detoxifies quinones), and γ-glutamylcysteine synthetase (the rate-limiting enzyme in glutathione synthesis). Reported potency is comparable to sulforaphane in NIH3T3 fibroblasts, with the induction of Nrf2 occurring at least partly through ERK (extracellular signal-regulated kinase, a stress-response signaling kinase) signaling.
NF-κB suppression and anti-inflammatory signaling: Iberin inhibits NF-κB (nuclear factor kappa B, a master transcription factor that drives inflammatory gene expression), STAT3 (signal transducer and activator of transcription 3, a transcription factor that promotes inflammation and cell proliferation), and the p70S6K-S6 ribosomal protein pathway (a signaling axis downstream of mTOR that controls protein synthesis and cell growth). These suppressions reduce TNF-α (tumor necrosis factor alpha, a key inflammatory cytokine), IL-6 (interleukin-6, an inflammatory cytokine), CXCL10 (a chemokine that recruits T cells to sites of inflammation), VCAM-1 (vascular cell adhesion molecule 1, an endothelial adhesion protein), iNOS (inducible nitric oxide synthase, an enzyme that produces inflammatory nitric oxide), and COX-2 (cyclooxygenase-2, an enzyme that produces pro-inflammatory prostaglandins).
Apoptosis induction via reactive oxygen species: Iberin elevates intracellular ROS (reactive oxygen species, chemically reactive molecules that at high levels can trigger cell death), depletes the GSH/GSSG ratio (the balance between reduced and oxidized glutathione, a measure of cellular redox status), and activates caspase-3 and caspase-9 (enzymes that execute the programmed cell death cascade). It downregulates GPX1 (glutathione peroxidase 1, an antioxidant enzyme), reinforcing the pro-oxidant tilt that triggers apoptosis selectively in transformed cells.
Cell cycle arrest: Iberin reduces expression of CDK2, CDK4, and CDK6 (cyclin-dependent kinases that drive cell cycle progression) and induces p21 (a cyclin-dependent kinase inhibitor that halts the cell cycle) through the transcription factor KLF4 (Kruppel-like factor 4, a regulator of cell differentiation and proliferation). This produces G1 or G2/M arrest depending on cell type.
Histone-modifying activity (epigenetics): Iberin reduces total histone deacetylase (HDAC) activity, modulates expression of specific histone deacetylases and acetyltransferases, and alters lysine acetylation and methylation marks on histones 3 and 4. These epigenetic effects are mechanistically distinct from Nrf2 activation and parallel those of sulforaphane.
Quorum sensing inhibition (antimicrobial): Iberin specifically blocks expression of QS-regulated genes in Pseudomonas aeruginosa, an opportunistic pathogen, without acting as a conventional bactericide. This represents a chemically distinct antimicrobial strategy and was the basis for identifying iberin as the active component of horseradish extract.

Where mechanistic interpretations differ: some authors emphasize iberin’s near-equivalent Nrf2 induction to sulforaphane and predict similar in-vivo cytoprotective effects, while others note that iberin is far less abundant than sulforaphane in commonly consumed crucifers (broccoli, broccoli sprouts) and is more abundant in cabbage and horseradish, which deliver substantially smaller amounts. The relative real-world contribution of iberin to total cruciferous-vegetable benefit is therefore an open question.

Pharmacological properties:

Half-life: In humans, after broccoli consumption iberin and its mercapturic acid metabolites are detectable in plasma and urine alongside sulforaphane. Plasma half-life is short — approximately 1.7–2 hours, similar to sulforaphane — based on the broader isothiocyanate pharmacokinetic literature. Downstream Nrf2-induced gene expression persists longer than the parent compound.
Selectivity: Reactive electrophile that modifies cysteine-rich sensor proteins, with Keap1 the most-studied target. Unlike sulforaphane, iberin does not significantly inhibit major hepatic CYP enzymes (cytochromes P450, a family of liver enzymes that metabolize most prescription drugs) — including CYP2A6 (metabolizes nicotine and certain drugs), CYP2C9 (metabolizes warfarin and many NSAIDs), CYP2C19 (metabolizes proton-pump inhibitors and clopidogrel), CYP2D6 (metabolizes many psychiatric and cardiovascular drugs), CYP2E1 (metabolizes alcohol and some toxins), and CYP3A4 (the most prolific drug-metabolizing enzyme, handling ~50% of prescription medications) — at tested concentrations, suggesting a cleaner drug-interaction profile.
Tissue distribution: Lipophilic small molecule absorbed in the small intestine; metabolites detectable in plasma and urine. Tissue distribution data in humans are limited.
Metabolism: Conjugated with glutathione via glutathione S-transferases and excreted as N-acetylcysteine and cysteine conjugates through the mercapturic acid pathway. The same GSTM1 (glutathione S-transferase mu 1, an enzyme that conjugates isothiocyanates with glutathione for elimination) and GSTT1 (glutathione S-transferase theta 1, a related conjugating enzyme) polymorphisms that govern sulforaphane clearance apply to iberin.

Historical Context & Evolution

Iberin was first isolated and named after the genus Iberis (candytuft, a small flowering Brassicaceae genus), from which its parent glucosinolate glucoiberin was originally characterized. Spectroscopic reference work on glucoiberin from Iberis amara in the early 2000s established the analytical fingerprint that supports modern phytochemical research on the compound. Glucoiberin has long been recognized as a major glucosinolate of cabbage and a minor component of broccoli, Brussels sprouts, kale, horseradish, and several other Brassicaceae.

Scientific interest in iberin’s biology emerged in the 2000s alongside the broader investigation of cruciferous-vegetable isothiocyanates following the 1992 discovery of sulforaphane at Johns Hopkins. Early laboratory work (Staack et al., 1998) compared iberin and other Brussels sprouts glucosinolate breakdown products and showed that several of these compounds, including iberin, induced phase II detoxification enzymes. The mid-2000s through 2010s saw a wave of cell-culture studies showing iberin’s anticancer activity in glioblastoma, neuroblastoma, melanoma, prostate, hepatocellular, and colon cancer lines, plus the demonstration that iberin specifically inhibits Pseudomonas aeruginosa quorum sensing — a finding that opened a new line of antimicrobial research independent of the cancer literature.

Translation to human work has lagged. Pharmacokinetic measurements of iberin in human plasma and urine after broccoli consumption (Al Janobi et al., 2006) confirmed that dietary iberin reaches the circulation, but no clinical trial has tested iberin as a standalone intervention for any health outcome. The compound remains primarily a laboratory tool and a component of cruciferous-vegetable exposure. Scientific opinion has neither dismissed nor embraced iberin as a discrete intervention; the prevailing view is that iberin contributes to the broader chemopreventive and antioxidant effects of cruciferous vegetables alongside sulforaphane and its other isothiocyanate siblings, with the relative contribution still under investigation.

Expected Benefits

A dedicated search for iberin’s full benefit profile was performed across PubMed, the broader isothiocyanate literature, and clinical trial registries before drafting this section. All identified evidence is preclinical (cell culture and rodent models); no human outcome data are available.

Low 🟩

Activation of Phase II Detoxification and Antioxidant Defense

Iberin reliably induces Nrf2 nuclear translocation and upregulates HO-1, NQO1, and γ-glutamylcysteine synthetase (a precursor to glutathione) in cell culture and rodent tissues, with potency comparable to sulforaphane. This represents iberin’s most consistently demonstrated and biologically plausible benefit. Human evidence is indirect: dietary iberin from broccoli reaches plasma, and isothiocyanate-induced Nrf2 activation in humans has been demonstrated for sulforaphane, but iberin-specific human induction studies have not been performed.

Magnitude: Comparable to sulforaphane in cell culture (low-micromolar concentrations); not quantified in humans.

Anti-Inflammatory Activity

Iberin reduces TNF-α-driven production of IL-6, CXCL10, VCAM-1, iNOS, and COX-2 in human oral epithelial cell models, and inhibits NF-κB, STAT3, and p70S6K-S6 signaling. In a rat model of renal ischemia-reperfusion injury, pre-injection of iberin (15 mg/kg) reduced IL-1β, IL-6, TNF-α, BAX (a pro-apoptotic protein that promotes cell death), HMGB1 (high mobility group box 1, a damage-associated inflammatory signal), and NGAL (neutrophil gelatinase-associated lipocalin, a kidney injury biomarker), and increased Bcl-2 (an anti-apoptotic protein) and heat shock protein expression. No human anti-inflammatory trials exist.

Magnitude: Significant reductions across multiple cytokines and adhesion molecules at low-micromolar in-vitro concentrations and 15 mg/kg in rats; no human magnitude.

Speculative 🟨

Cancer Chemoprevention

Cell-culture studies report iberin-induced apoptosis and cell cycle arrest in ovarian (Gong et al., 2021), glioblastoma (Jadhav et al., 2007), neuroblastoma (Jadhav et al., 2007), melanoma (Mitsiogianni et al., 2021), hepatocellular (Pocasap et al., 2019), prostate (Chambers et al., 2009; Núñez-Iglesias et al., 2019), colon (Jakubikova et al., 2006), and lung adenocarcinoma (Wang et al., 2016) cell lines, plus a 2025 melanoma study using iberin from Cakile edentula. A single in-vivo ovarian-cancer xenograft study in nude mice supported anti-tumor activity. No human cancer trials of iberin have been conducted; the basis is preclinical and mechanistic.

Antimicrobial Activity Against Pseudomonas aeruginosa

Iberin from horseradish was identified as a quorum sensing inhibitor of P. aeruginosa, blocking expression of virulence-related genes in the bacterium (Jakobsen et al., 2012). A 2023 study (Dahshan et al.) reported that iberin combined with photodynamic antimicrobial chemotherapy enhanced bactericidal effects against P. aeruginosa biofilm in an ex vivo wound model. Activity has not been tested in human infections.

Soluble Epoxide Hydrolase Inhibition

A 2024 enzyme-screening study (Elbarbry et al.) reported that iberin, alongside several other natural isothiocyanates (ITCs), modestly inhibits soluble epoxide hydrolase (an enzyme whose inhibition is being explored for hypertension, pain, and inflammation). In the same study, sulforaphane and phenyl isothiocyanate were the most potent (IC₅₀ values 3.65 and 7.5 μM); iberin was less potent. Iberin and erucin (a related isothiocyanate) were notably the only ITCs that did not inhibit any of the tested CYP enzymes, suggesting a cleaner drug-interaction profile than sulforaphane.

Renal Ischemia-Reperfusion Protection

The 2023 Yahiya et al. rat study (15 mg/kg pre-injection, 30 min ischemia, 2 h reperfusion) reported reductions in inflammatory and apoptotic markers and increases in Bcl-2 and heat shock proteins. The basis is a single small-animal model.

Epigenetic Modulation

Iberin alters histone deacetylase activity and lysine acetylation/methylation marks in melanoma cell lines (Mitsiogianni et al., 2021). The translational significance for cancer or aging endpoints is unestablished.

Benefit-Modifying Factors

Because no human iberin trials have been performed, all factors below are inferred from the broader isothiocyanate literature, particularly studies of sulforaphane sharing the mercapturic-acid metabolic pathway:

Genetic polymorphisms: GSTM1 and GSTT1 null genotypes — present in 20–50% of populations — slow isothiocyanate clearance and yield higher and more sustained plasma levels. The directionality of effect on benefit varies by endpoint: slower clearance can both prolong Nrf2 activation and reduce mercapturic-acid excretion of carcinogens, depending on tissue and outcome.
Baseline biomarker levels: Individuals with elevated baseline oxidative stress or chronic low-grade inflammation may show larger Nrf2-induction responses, mirroring the pattern observed for sulforaphane.
Sex-based differences: No iberin-specific sex differences have been characterized. Sex-based differences in cruciferous-vegetable isothiocyanate metabolism more broadly have been suggested but not consistently demonstrated.
Pre-existing health conditions: Conditions associated with high oxidative stress (cardiovascular disease, type 2 diabetes, chronic kidney disease) may yield larger relative Nrf2-mediated benefit. Pre-existing cruciferous-vegetable allergy is an absolute contraindication for concentrated exposure.
Age: Nrf2 responsiveness declines with age. Older adults may experience smaller acute Nrf2 induction but could also benefit more from any successful induction given higher baseline oxidative damage.
Gut microbiome composition: Inter-individual variation in myrosinase-active gut bacteria (e.g., Enterococcus casseliflavus) and in glucosinolate-to-nitrile-converting bacteria (e.g., Clostridiaceae and Enterobacteriaceae taxa) affects how much iberin versus inactive iberin-nitrile is generated from glucoiberin. People with low myrosinase-active microbiota may produce substantially less iberin from cooked cruciferous vegetables.

Potential Risks & Side Effects

A dedicated search of PubMed, the broader isothiocyanate safety literature, and food-safety databases was performed before drafting this section. No human adverse-event data exist for iberin specifically; the entries below are inferred from class-level isothiocyanate safety and from cruciferous-vegetable consumption data.

Low 🟥

Gastrointestinal Discomfort

The most common adverse effect reported across cruciferous-vegetable and isothiocyanate trials, occurring in approximately 10–25% of participants in sulforaphane studies and likely applicable to iberin given shared chemistry. Symptoms include flatulence, mild abdominal discomfort, loose stools, and nausea; effects are generally mild, dose-related, and resolve with continued exposure or reduced intake.

Magnitude: Not quantified in available studies.

Allergic Reaction

Hypersensitivity to cruciferous vegetables and isolated isothiocyanates has been reported in case reports as contact dermatitis and, very rarely, anaphylactic reactions. Individuals with known cruciferous allergy should avoid concentrated iberin sources.

Magnitude: Not quantified in available studies.

Speculative 🟨

Goitrogenic Potential

Cruciferous vegetables and the broader isothiocyanate class can interfere with iodide uptake by the thyroid in iodine-deficient individuals. Effects are modest at typical dietary intakes and largely absent in iodine-replete populations. Iberin-specific thyroid data do not exist; risk is inferred from class effects.

Pro-oxidant Effects at High Concentrations

Iberin generates reactive oxygen species in cancer-cell models, which is the proposed apoptotic mechanism. At very high concentrations achievable in cell culture but unlikely with dietary exposure, this pro-oxidant tilt could theoretically harm normal cells. Whether such concentrations are achievable in human tissues at any plausible dietary intake is unclear; basis is in-vitro only.

Drug-Metabolism Interactions

Unlike sulforaphane, iberin did not inhibit CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 in liver microsome screening (Elbarbry et al., 2024), suggesting a relatively clean phase I drug-interaction profile. However, iberin shares the mercapturic-acid pathway with other isothiocyanates and could in theory compete for glutathione conjugation in patients on glutathione-depleting medications. No human drug-interaction data exist.

Risk-Modifying Factors

Genetic polymorphisms: GSTM1- and GSTT1-null individuals may have higher peak plasma iberin concentrations and slightly elevated risk of dose-related gastrointestinal effects, though the absolute risk remains low at dietary intakes.
Baseline iodine status: Iodine-deficient individuals are at theoretical risk of goitrogenic effects from chronic high cruciferous-vegetable consumption. Adequate dietary iodine substantially mitigates this risk.
Sex-based differences: No iberin-specific sex differences in adverse event profile have been established.
Pre-existing health conditions: Individuals with active gastrointestinal inflammation, severe iodine deficiency, or known cruciferous-vegetable allergy face elevated risk from concentrated isothiocyanate exposure. Pregnancy warrants caution with concentrated forms given lack of data, though dietary cruciferous intake is considered safe.
Age: Older adults and very young children have less robust glutathione regeneration capacity, potentially altering tolerance of high-dose isothiocyanate exposure. No iberin-specific age data exist.

Key Interactions & Contraindications

Prescription drug interactions: No human drug-interaction studies of iberin have been performed. In vitro, iberin showed no significant inhibition of major hepatic CYP enzymes, suggesting a cleaner profile than sulforaphane. Theoretical glutathione-depletion competition with paracetamol/acetaminophen overdose, busulfan, and high-dose acetaminophen exists for the isothiocyanate class. Caution is the appropriate stance for narrow-therapeutic-window medications.
Over-the-counter medication interactions: Anti-inflammatory NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, aspirin, and naproxen) act on COX-2 and may have additive anti-inflammatory effects with iberin’s COX-2 suppression at high exposures. Severity: monitor.
Supplement interactions: Other Nrf2 activators (sulforaphane, curcumin, resveratrol, broccoli sprout extract) may produce additive effects. NAC (N-acetylcysteine, a glutathione precursor) provides substrate for iberin’s primary clearance pathway. Severity: caution at high combined doses; clinical consequence is uncertain but theoretical antioxidant overdrive cannot be ruled out.
Other intervention interactions: Concurrent use of ITC-rich foods (broccoli sprouts, watercress, mustard, horseradish) with iberin-containing supplements would deliver overlapping isothiocyanate exposure. Mitigating action: monitor total intake.
Levothyroxine and thyroid hormone replacement: Caution. Chronic high-dose isothiocyanate exposure combined with iodine deficiency could theoretically necessitate thyroid-hormone dose adjustment. Mitigating action: ensure iodine sufficiency; recheck TSH (thyroid-stimulating hormone, the pituitary signal that drives thyroid output) at 6–12 weeks if intake increases substantially.
Anticoagulants and antiplatelet drugs (warfarin, clopidogrel, aspirin): Caution. Cruciferous vegetables contain vitamin K, which antagonizes warfarin. The cruciferous-vegetable intake itself is the relevant interaction, not iberin per se; mitigation is consistent dietary intake to allow stable INR (international normalized ratio, a measure of clotting time).
Populations who should avoid: Individuals with known cruciferous-vegetable allergy (absolute contraindication for concentrated forms). Individuals with severe untreated iodine deficiency should achieve iodine sufficiency before sustained high cruciferous-vegetable intake. Pregnant and breastfeeding women should rely on dietary cruciferous intake rather than concentrated extracts given the absence of pregnancy safety data for iberin specifically. Individuals with active gastrointestinal inflammation (acute gastritis, peptic ulcer, active inflammatory bowel disease (IBD, a group of chronic conditions causing intestinal inflammation including Crohn’s disease and ulcerative colitis) flare) should exercise caution with concentrated isothiocyanate exposure.

Risk Mitigation Strategies

Obtain iberin through dietary cruciferous vegetable intake: Cabbage, broccoli, broccoli sprouts, Brussels sprouts, kale, collards, and horseradish provide iberin in food-matrix amounts that have been consumed safely for centuries. This mitigates the unknown safety of concentrated iberin exposure.
Confirm iodine sufficiency before sustained high cruciferous intake: Test thyroid panel (TSH, free T4) or urinary iodine before substantially increasing cruciferous-vegetable consumption. Supplement iodine (target 150 μg/day from diet or multivitamin) if borderline. This mitigates the goitrogenic risk identified above.
Start gradually to reduce gastrointestinal discomfort: Increase cruciferous-vegetable intake over 1–2 weeks rather than abruptly, particularly for individuals unaccustomed to high-fiber Brassicaceae. This mitigates the dose-related GI discomfort that affects 10–25% of users in related sulforaphane trials.
Maximize myrosinase activation through preparation: Raw consumption or light steaming preserves the plant myrosinase needed to convert glucoiberin to iberin. Crushing or chopping cabbage or broccoli and waiting 30–40 minutes before cooking allows iberin to form before heat denatures myrosinase. Adding mustard seed powder (a rich myrosinase source) to cooked cruciferous vegetables can restore conversion.
Recheck TSH at 6–12 weeks of high-dose exposure: Detects sub-clinical thyroid shifts before they progress; relevant for those with prior hypothyroidism or borderline iodine status.
Avoid concentrated standalone iberin extracts pending human safety data: Standalone iberin supplements are not commercially marketed for health use. Research-grade iberin is intended for laboratory use, not human consumption. This mitigation reflects the absence of safety data for any concentrated iberin preparation.

Therapeutic Protocol

No therapeutic protocol exists for iberin. There are no human clinical trials of iberin as a standalone intervention, no commercially available iberin supplements marketed for health, and no expert consensus on dosing for any health endpoint. The closest practical approach is dietary modulation of total isothiocyanate exposure through cruciferous vegetables containing glucoiberin.

Dietary approach (primary): Regular consumption of cruciferous vegetables high in glucoiberin — cabbage (red and green), Brussels sprouts, kale, collards, broccoli, and horseradish — provides iberin alongside other isothiocyanates. Fermented cabbage preparations (sauerkraut, kimchi) made with myrosinase-positive bacteria can substantially increase iberin yield: a Thai fermented cabbage study using Enterobacter xiangfangensis generated iberin at approximately 117 μmol/100 g dry weight after 2 days, alongside higher sulforaphane content.
Competing therapeutic approaches: No comparative human protocols exist. Researchers and integrative practitioners working with cruciferous-vegetable interventions generally recommend a mix of raw or lightly cooked cruciferous vegetables (to preserve myrosinase) and fermented cruciferous foods (which deliver pre-formed isothiocyanates). The Linus Pauling Institute and Life Extension framing favors broader cruciferous intake over targeting any single isothiocyanate.
Best time of day: No iberin-specific data. By analogy to sulforaphane (plasma half-life ~1.7–2 hours), distributing cruciferous intake across two daily meals would maintain steadier exposure than a single bolus.
Half-life: Plasma half-life is approximately 1.7–2 hours based on Al Janobi et al. (2006) measurements of iberin and its mercapturic-acid metabolites in human plasma after broccoli consumption, similar to sulforaphane. Downstream Nrf2-induced gene expression persists 24–72 hours, allowing once- or twice-daily dietary spacing.
Single dose vs. split doses: Given the short plasma half-life, splitting cruciferous intake across two meals is theoretically preferable to a single large serving for sustained Nrf2 induction; no head-to-head data exist for iberin.
Genetic polymorphisms: GSTM1- and GSTT1-null individuals (20–50% of populations) clear isothiocyanates more slowly. No iberin-specific dose adjustments exist.
Sex-based differences: No iberin-specific sex-based dosing data.
Age: No iberin-specific age-related dosing data. Older adults with reduced gut myrosinase-active microbiota may benefit from preparing cruciferous vegetables in ways that preserve plant myrosinase (e.g., the chop-and-wait method or adding mustard powder).
Baseline biomarker levels: No iberin-specific baseline thresholds guide intake. By analogy to sulforaphane, individuals with elevated baseline oxidative stress markers (higher hs-CRP — high-sensitivity C-reactive protein, a sensitive marker of systemic inflammation — or oxLDL — oxidized low-density lipoprotein, an oxidative damage marker) may experience larger relative Nrf2 induction.
Pre-existing conditions: Individuals with active GI inflammation should introduce cruciferous-vegetable increases gradually; those with iodine deficiency should correct iodine status first.

Discontinuation & Cycling

Lifelong vs. short-term: Cruciferous-vegetable intake — the practical vehicle for iberin exposure — is intended for lifelong inclusion in the diet, not as a short-term intervention. There is no established maximum duration.
Withdrawal effects: None known. Discontinuation simply removes ongoing Nrf2 activation; no rebound or withdrawal phenomena have been described for iberin or for cruciferous vegetables more broadly.
Tapering: Not applicable for dietary iberin intake.
Cycling: No evidence supports or contradicts cycling for maintaining iberin or isothiocyanate efficacy. Some practitioners argue that continuous Nrf2 stimulation may downregulate response over time, while others see no human evidence for tachyphylaxis (a diminishing response with continued exposure). No data exist to settle this question for iberin specifically.

Sourcing and Quality

Dietary source: Cabbage (red and green), Brussels sprouts, kale, collards, horseradish, and broccoli are the primary dietary sources of glucoiberin. Cabbage contains substantially more glucoiberin than broccoli. Fresh, raw, or lightly cooked preparation preserves myrosinase activity for iberin conversion.
Concentrated supplements: No standalone iberin supplements are commercially marketed for health purposes. Some broccoli-sprout and cruciferous-extract supplements may contain iberin alongside sulforaphane and other isothiocyanates, but iberin content is rarely standardized or disclosed.
Research-grade iberin: Available from chemical suppliers (Cayman Chemical, Sigma-Aldrich, LKT Labs, APExBIO) for laboratory use. These products are not intended for human consumption and have no safety, purity, or quality attestation appropriate for ingestion.
Cabbage and horseradish quality: Fresh, vibrant cabbage and freshly grated horseradish provide the highest yields of iberin. Aged or commercially processed prepared horseradish loses isothiocyanate content over time.
Cruciferous-extract quality considerations: For broccoli-sprout extracts that may incidentally contain iberin, third-party testing for sulforaphane content (the standardized marker), heavy-metal contamination, and microbial contamination is the relevant quality framework. Brands with USP, NSF, or ConsumerLab third-party verification on related broccoli products provide a partial quality proxy for any iberin co-content.
Organic and pesticide considerations: Cruciferous vegetables can accumulate sulfur-rich compounds and pesticide residues; organic produce reduces pesticide exposure but does not affect glucoiberin content meaningfully.

Practical Considerations

Time to effect: Unknown for iberin specifically. Nrf2-mediated enzyme induction begins within hours in cell models. Functional effects on inflammation and oxidative stress markers, by analogy to sulforaphane, typically require weeks of consistent intake.
Common pitfalls: Overcooking cruciferous vegetables destroys myrosinase and dramatically reduces iberin yield from glucoiberin; boiling for more than a few minutes is particularly destructive. Discarding the cooking water further reduces total isothiocyanate intake when myrosinase has not been preserved. Relying on supplements without verified iberin content provides no assurance of meaningful exposure.
Regulatory status: Iberin is not a regulated drug or supplement in any major jurisdiction. It is a constituent of cruciferous vegetables, which are GRAS (generally recognized as safe) food components. Research-grade iberin is sold as a chemical reagent and is not authorized for human consumption.
Cost and accessibility: Iberin is not directly available as a consumer supplement. Dietary sources (cabbage, broccoli, kale, horseradish) are widely available and inexpensive, making iberin one of the most accessible isothiocyanates by food source even without supplementation.

Interaction with Foundational Habits

Sleep: No direct iberin–sleep data exist. Nrf2 activation has weak indirect effects on sleep through inflammation reduction. Cruciferous vegetables eaten close to bedtime can cause GI discomfort in sensitive individuals, indirectly disrupting sleep. Direction: indirect, weak.
Nutrition: Iberin formation is governed by food preparation. The “chop and wait 30–40 minutes” method allows endogenous plant myrosinase to convert glucoiberin to iberin before cooking denatures the enzyme. Adding mustard seed powder (a concentrated myrosinase source) to cooked cruciferous vegetables restores some conversion. Combining cruciferous vegetables with adequate iodine intake (seafood, iodized salt) mitigates goitrogenic potential. Direction: direct, potentiating with proper preparation; blunting if overcooked.
Exercise: Exercise itself activates Nrf2 in skeletal muscle. Combined exercise plus dietary iberin intake may produce additive Nrf2 activation, mirroring observations for sulforaphane and other isothiocyanates, though no controlled iberin-exercise studies exist. Direction: potentiating (theoretical).
Stress management: No direct iberin–stress data. Chronic psychological stress impairs Nrf2 responsiveness, suggesting that Nrf2-targeted compounds including iberin may be less effective against the inflammatory burden of chronic stress without parallel stress mitigation. Direction: indirect; combined approach favored.

Monitoring Protocol & Defining Success

Because iberin has no established human therapeutic application, no formal monitoring protocol is required for dietary intake of cruciferous vegetables containing iberin. The biomarkers below apply when an individual significantly increases cruciferous-vegetable intake or chooses high-isothiocyanate supplementation that may incidentally contain iberin.

Baseline testing is appropriate before substantially increasing cruciferous-vegetable intake or starting any concentrated isothiocyanate supplement. Ongoing monitoring should follow a cadence of approximately every 6–12 months, or 6–12 weeks after a major intake change.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
TSH (thyroid-stimulating hormone)	0.4–2.5 mIU/L	Detects sub-clinical thyroid shifts during high cruciferous intake	Conventional reference range often extends to 4.5 mIU/L; functional medicine targets the lower portion. Measure in the morning, ideally fasting
Free T4	1.0–1.5 ng/dL	Confirms thyroid hormone production is adequate	Pair with TSH for full thyroid screen
Urinary iodine	100–199 μg/L (population sufficiency)	Confirms iodine status before sustained cruciferous-vegetable increase	Single spot test reflects recent intake; multiple measurements give better individual estimate
hs-CRP (high-sensitivity C-reactive protein)	<1.0 mg/L	Assesses systemic inflammatory burden potentially modifiable by Nrf2 activation	Acute infections artificially elevate; retest if recent illness
CMP	Within standard reference range	Baseline kidney and liver function before any concentrated isothiocyanate supplement	CMP = Comprehensive metabolic panel (a standard blood chemistry test covering electrolytes, kidney, and liver markers); annual frequency sufficient at typical dietary intake
CBC	Within standard reference range	General health screen and detection of any allergic or inflammatory shifts	CBC = Complete blood count (a standard blood test measuring red cells, white cells, and platelets); annual or as clinically indicated
Genotype: GSTM1, GSTT1 (one-time)	Null vs. positive	Identifies individuals with slower isothiocyanate clearance	One-time test through commercial pharmacogenetic panel; informs long-term dosing context

Qualitative markers worth tracking (no single measurement defines success):

Subjective digestive tolerance (flatulence, stool consistency, abdominal discomfort)
Energy levels, particularly in the days following a substantial cruciferous-meal increase
Skin appearance and any rash or contact-dermatitis signs (allergic indicator)
Cold tolerance, fatigue, or unexplained weight changes that could signal thyroid drift

Emerging Research

No active iberin-specific clinical trials: A search of clinicaltrials.gov (April 2026) returned no studies with iberin as the named intervention. Iberin remains exclusively in preclinical research as of the creation date.
Cabbage-fermentation iberin yield optimization: Active food-science work is exploring myrosinase-positive bacterial strains for fermenting cabbage to maximize iberin and sulforaphane yields (Luang-In et al., 2018). This could underpin functional-food formulations delivering substantially higher iberin than typical dietary intake.
Carbohydrate-based iberin analogues: A 2025 medicinal-chemistry study (Prieto et al., 2025) reported a series of carbohydrate-based iberin analogues with anticancer and antioxidant activity, including improved Nrf2-induction profiles compared to the parent compound. This direction could yield more drug-like iberin derivatives suitable for human investigation.
Soluble epoxide hydrolase inhibitor screening: The 2024 Elbarbry et al. work (PMID 38897040) suggests iberin and erucin are candidate sEH (soluble epoxide hydrolase) inhibitors with cleaner CYP profiles than sulforaphane. Further selectivity work could position these compounds as safer Nrf2-active templates.
Gut microbiome influence on iberin yield: Continued work by the Linus Pauling Institute group (Bouranis et al., 2021) is mapping how gut microbiome composition determines whether glucoiberin yields active iberin or inactive iberin-nitrile. This may enable personalized cruciferous-vegetable recommendations based on microbiome profile.
Studies that could weaken the case: A bioactivity-guided characterization study (Jeong et al., 2025) confirmed iberin’s apoptotic activity in melanoma cells but again only in vitro. Continued failure to translate iberin’s preclinical signal into human outcome data over the coming years would weaken the case for any standalone intervention. The lack of any registered human trial of iberin as of April 2026 is itself a noteworthy negative signal.
Future research areas: Phase I human pharmacokinetic and tolerability studies of pre-formed iberin or iberin-enriched cabbage extracts; head-to-head iberin vs. sulforaphane biomarker comparisons in healthy volunteers; trials of iberin-rich fermented cabbage in cardiometabolic or inflammatory endpoints.

Conclusion

Iberin is one of several lesser-known cruciferous-vegetable isothiocyanates living in the shadow of sulforaphane. Cabbage, Brussels sprouts, kale, broccoli, and horseradish all generate iberin from the parent molecule glucoiberin when their tissues are damaged. Laboratory work shows that iberin can switch on the same internal antioxidant and detoxification defenses that sulforaphane activates, can dampen inflammatory signaling, can trigger programmed cell death in a wide range of cancer cell lines, and can interfere with the chemical communication used by an opportunistic bacterium common in hospital-acquired infections.

The evidence base is essentially preclinical. No human trial has tested iberin as a standalone intervention for any condition, and no commercial supplement targets iberin specifically. Whatever exposure individuals obtain comes from dietary cruciferous-vegetable intake, where iberin is one constituent among many. The available evidence speaks to cruciferous-vegetable consumption rather than to iberin as a discrete agent.

Practical risks at dietary intake levels are modest and largely shared with the broader cruciferous-vegetable category: mild gastrointestinal effects in some individuals, a theoretical thyroid concern in iodine-deficient populations, and rare allergic responses. The notable advantage of iberin in early data is a cleaner drug-interaction profile than sulforaphane. The realistic place for iberin in a longevity-oriented framework is as part of habitual cruciferous-vegetable intake, with attention to preparation that preserves the enzymatic conversion needed to form it.

Top - Benefits - Risks - Protocol

Iberin for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Low 🟩

Activation of Phase II Detoxification and Antioxidant Defense

Anti-Inflammatory Activity

Speculative 🟨

Cancer Chemoprevention

Antimicrobial Activity Against Pseudomonas aeruginosa

Soluble Epoxide Hydrolase Inhibition

Renal Ischemia-Reperfusion Protection

Epigenetic Modulation

Benefit-Modifying Factors

Potential Risks & Side Effects

Low 🟥

Gastrointestinal Discomfort

Allergic Reaction

Speculative 🟨

Goitrogenic Potential

Pro-oxidant Effects at High Concentrations

Drug-Metabolism Interactions

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion